Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG

Short bowel syndrome with intestinal failure (SBS-IF)

15K US cases/yr · $930M Gattex / Revestive (teduglutide) 2023 global sales — current GLP-2 category anchor · 1000 Ironwood-VectivBio deal size (USD MM, net of cash and debt)

Disease Overview

Short bowel syndrome with intestinal failure (SBS-IF) is an ultra-rare, chronically debilitating condition in which surgical resection or congenital loss of small intestine reduces absorptive capacity below the threshold required to maintain fluid, electrolyte and nutritional balance, forcing patients onto lifelong parenteral support (PS). Prevalence estimates vary but sit at roughly 15,000 to 25,000 adults and children in the United States (Takeda / Shire historical estimates and NORD), with adult SBS-IF alone estimated at 10,000-18,000 US patients. Patients typically require PS infusions 5-7 nights per week, each lasting 10-14 hours, with catheter-related bloodstream infections, central venous thrombosis, and intestinal-failure-associated liver disease as the principal morbidity and mortality drivers; five-year mortality on long-term PS is approximately 30%. The approved GLP-2 analog, teduglutide (Gattex / Revestive, Takeda), requires daily subcutaneous injection and generated ~$930M in 2023 sales, with the key commercial limit being daily adherence and a long titration to PS reduction. Apraglutide (VectivBio) is a next-generation long-acting GLP-2 analog designed for once-weekly subcutaneous dosing and better receptor pharmacology, positioned as a potential best-in-class follow-on and the principal strategic asset behind Ironwood's $1B acquisition.

Competitive Landscape

The SBS-IF competitive landscape is narrow and protein-therapeutic dominated. Current standard: teduglutide (Gattex US / Revestive ex-US, Takeda / Shire) — first-in-class GLP-2 analog, daily subcutaneous, approved 2012 US, $930M 2023 sales, loss of exclusivity approaching late decade. Next-generation GLP-2 analogs: apraglutide (VectivBio, now Ironwood) — long-acting, once-weekly SC, Phase 3 STARS program positive topline 2024; glepaglutide (Zealand Pharma) — twice-weekly SC, Phase 3 EASE programs, CRL issued by FDA 2023 for manufacturing, resubmission pending. GLP-1 / combination mechanisms under exploration: liraglutide adjunctive use (academic); dapiglutide (9 Meters Biopharma — program discontinued 2023). Upstream absorptive / growth factor approaches: GATTEX-like teduglutide formulation work at Takeda; oxyntomodulin analogs (preclinical). Non-GLP-2 mechanisms remain largely academic. Parenteral support optimization (Smoflipid lipid emulsions, reduced-infusion regimens) represents the non-drug comparator set but does not displace GLP-2 for responders. Ironwood's thesis is that weekly apraglutide could meaningfully reduce or eliminate PS dependency where daily Gattex has plateaued.